Fasting is not a shortcut
Intermittent fasting should not replace product-specific review
Peptide12-listed products raise different fasting questions. Semaglutide and tirzepatide may reduce appetite and cause gastrointestinal side effects for some patients. Sermorelin, NAD+, glutathione, PT-141, GHK-Cu, and methylene blue have different goals, routes, and medication-review needs. A clinician should decide whether fasting is appropriate for your diagnosis, nutrition status, labs, medications, and treatment goal.
- Ask whether fasting fits the reason you are seeking care: weight management, energy, recovery, skin or hair support, sexual health, healthy aging, or another goal.
- Share prior disordered eating, restrictive dieting, bariatric surgery, pregnancy possibility, diabetes, kidney or liver disease, reflux, gallbladder history, and current exercise load.
- Compounded finished drug products are not FDA-approved; fasting, side-effect, and dose-change instructions should come from the prescriber and dispensing pharmacy.